Drug research

Zanzalintinib

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as XL092

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
A Study of Zanzalintinib in Participants With Recurrent or Progressive MeningiomaNCT07428616	Exelixis	Phase 2	Recruiting	2028-02-29Estimated
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyNCT07620574	Exelixis	Phase 3	Enrolling by invitation	2030-05-31Estimated
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsNCT06943755	Exelixis	Phase 2, Phase 3	Recruiting	2029-06-30Estimated
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNCT06082167	Exelixis	Phase 2, Phase 3	Active not recruiting	2028-08Estimated

ExelixisRecruitingPrimary completion: 2028-02-29 · Estimated

Trial details

ExelixisEnrolling by invitationPrimary completion: 2030-05-31 · Estimated

Trial details

ExelixisRecruitingPrimary completion: 2029-06-30 · Estimated

Trial details

ExelixisActive not recruitingPrimary completion: 2028-08 · Estimated

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.